Use of antenatal magnesium sulfate for neuroprotection: a survey of national practices

Shivshankar Diggikar, Srikanth Kulkarni, Abhishek S. Aradhya, Praveen Venkatagiri


This web-based cross-sectional survey suggests that uptake of antenatal magnesium sulfate for babies<32 weeks is about 75.2% (67/89) of centres in India, more in private sector hospitals 53/66 (80.3%) compared to public sector hospitals 14/23 (60.8%). A written policy for managing babies<32 weeks is available in 62.9% of units. Adequate facilities were available in 94.3% of units to administer magnesium sulfate. Although there is adequate knowledge (89.8%) about the beneficial effects of antenatal magnesium sulfate, attitude, and practice seem to be the major hurdle in implementation.  


Magnesium sulfate, Neuroprotection, Survey

Full Text:



Blencowe H, Cousens S, Oestergaard M, Chou D, Moller A, Narwal R. et al. National, Regional, and Worldwide Estimates of Preterm Birth Rates in the Year 2010 With Time Trends Since 1990 for Selected Countries. Obstetric Anaesthesia Digest. 2013;33(3):142.

Chauhan A, Singh M, Jaiswal N, Agarwal A, Sahu J, Singh M. Prevalence of Cerebral Palsy in Indian Children: A Systematic Review and Meta-Analysis. Ind J Pediat. 2019;86(12):1124-30.

Crowther C, Middleton P, Voysey M, Askie L, Duley L, Pryde P, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLOS Med. 2017;14(10):e1002398.

WHO recommendation on the use of magnesium sulphate for fetal protection from neurological complications. Available at: http://extranet. Accessed on 14 April 2020. Available at: Accessed on 18 April 2020.

National Neonatology Forum Accredited Centres. Available at: accreditation/NNFAccreditationAssessmentUndertakenasperRevisedLevelIIGuidelines.pdf. Accessed on 17 April 2020.

Nightingale Internet Reporting System. Vermont oxford network database of very low birth weight infants born in 2012. Burlington, VT: Vermont Oxford Network.

Wolf H, Huusom L, Weber T, Piedvache A, Schmidt S, Norman M et al. Use of magnesium sulfate before 32 weeks of gestation: a European population-based cohort study. Bio Med J Op. 2017;7(1):e013952.

De Silva D, Synnes A, von Dadelszen P, Lee T, Bone J, Magee L. Magnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada. Implementation Science. 2018;13(1).

Burhouse A, Lea C, Ray S, Bailey H, Davies R, Harding H, et al. Preventing cerebral palsy in preterm labour: a multiorganizational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection. Bio Med J Op Qual. 2017;6(2):e000189.